Screener / SEC EDGAR /CIK 0001756262 /10-K filed Feb 24, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Devices

TransMedics Group, Inc. TMDX

Compare with peers Embed
The 10-K against last year's

136 changes: 28 added, 13 removed, 91 reworded, 4 quiet changes

10-K Feb 24, 2026 vs Feb 27, 2025

10-K 0001193125-26-067032 (Feb 24, 2026) vs 10-K 0000950170-25-029104 (Feb 27, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

320 paragraphs · 17 new · 67 reworded · 3 gone · 10-K Feb 24, 2026 against Feb 27, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 279 · 49% changed Every version of it
As we grow our international presence, we are increasingly exposed subject to trade and economic anti-corruption laws, anti-money laundering laws, export control laws, customs laws, sanctions laws and other restrictions laws and regulations imposed by the United States, the European Union and other governments and organizations. organizations in countries where we operate. The U.S. Departments of Justice, Commerce, State and State, and the U.S. Treasury and other federal agencies and authorities have authorities, may seek to impose a broad range of civil and criminal penalties they may seek to impose against corporations and individuals for violations of economic sanctions laws, export control laws, the FCPA FCPA, and other federal statutes and regulations, including those established by the Office of Foreign Assets Control, or OFAC. In addition, the Bribery Act prohibits both domestic and international bribery, as well as bribery across both private and public sectors. The substantive offences of offering or receiving a bribe will be committed by an individual where either the bribery takes place in the U.K, or the person paying or receiving the bribe has a close connection with the UK An organization which is either incorporated in or carries on part of its business in the U.K will be liable under the Bribery Act if a person associated with the organization (being persons performing services for it) pays a bribe anywhere in the world intending to obtain or retain business for the organization. This is a strict liability offense with the only defenses available being that the organization implemented “adequate procedures” to prevent bribery or it was reasonable for it to not have such procedures in place. Under these laws and regulations, as well as other anti-corruption laws, anti-money laundering laws, export control laws, customs laws, sanctions laws and other laws governing our operations, various government agencies may require export licenses, may seek to impose modifications to business practices, including cessation of business activities in sanctioned countries or with sanctioned persons or entities and modifications to compliance programs, which may increase compliance costs, and may subject us to fines, penalties and other sanctions. A violation of these laws or regulations would negatively affect our business, financial condition and results of operations. Due to sales of our products to government or government-affiliated entities, we may be exposed to heightened risk of potential violations of the FCPA, the Bribery Act, or other relevant law.
Paragraph 255 · 48% changed Every version of it
Counterfeit medical devices are an increasing presence on the market. Third parties may seek to develop, manufacture, distribute and sell systems that we believe infringe our proprietary rights, which would compete against the OCS and impair our ability to sell the OCS in jurisdictions in which our proprietary rights are not upheld. In addition, counterfeit products may be promoted in a way that misleads consumers into believing they are affiliated with us. If a counterfeit version of the OCS were to appear on the market, we would expect to be obliged to verify all OCS products currently on the market, and possibly to withdraw all OCS products from the market while verifications are made. We also might be named in a lawsuit relating to any side effects or fatalities allegedly related to the use of a counterfeit OCS irrespective of whether the counterfeit device in fact contributed to such an adverse event or whether we were aware of the existence of the counterfeit device.
Paragraph 164 · 47% changed Every version of it
Economic, political Our international expansion may expose us to operational, compliance and other financial risks associated with foreign operations that could adversely affect our international sales business and our results of operations.
Paragraph 119 · 47% changed Every version of it
Our aircraft fleet requires regular maintenance work, which may cause operational disruption. Failure to perform timely maintenance and repairs results in aircraft being underutilized which could have an adverse impact on our business, financial condition and results of operations. On occasion, airframe manufacturers and/or regulatory authorities require mandatory or recommended modifications across a particular fleet which may ground a particular type of aircraft. This may cause operational disruption to, and impose significant costs on us. Furthermore, our operations in remote locations, where delivery of components and parts or transportation of maintenance personnel could take a significant period of time, could result in delays in our ability to maintain and repair our aircraft. Any such delays may pose a risk to our business, financial condition and results of operations. Moreover, as our aircraft base increases and our fleet ages, our maintenance costs could potentially increase and we may be unable to manage the composition of our fleet in a manner that reduces costs due to the availability and prices for replacement aircraft and parts. When our aircraft are grounded for maintenance, we are required to rely on third-party logistics service providers to transport organs for our NOP, which increases the cost of operating our NOP.
Paragraph 294 · 44% changed Every version of it
Our products have been and may in the future be subject to product recalls that U.S. federal government shutdowns could harm our reputation and could materially and adversely affect our business, financial condition, operating results, cash flows and prospects.
Paragraph 61 · 43% changed Every version of it
Directors of transplant programs are key decision-makers in the adoption of novel medical devices used in organ transplantation. An important part of our commercialization efforts is to educate transplant center program directors and other surgeons on the relative merits of the OCS. Our success depends, in large part, on effectively marketing and educating program directors and other surgeons about the benefits of the OCS and our NOP. Acceptance of the OCS also depends on educating program directors, other surgeons and private and public payors as to the distinctive characteristics, perceived medical and economic benefits, safety, ease of use and cost-effectiveness of the OCS and our NOP. If program directors, other surgeons and private and public payors do not find our body of published clinical evidence and data compelling or wish to wait for additional studies, they may choose not to use or provide coverage and reimbursement for our products and NOP Services. Currently, most universal national healthcare systems outside of the United States do not reimburse transplant centers for the use of the OCS and reimbursement in international markets may require us to undertake additional clinical studies.
Paragraph 238 · 39% changed Every version of it
In international markets, market acceptance of our products will likely depend in large part on the availability of reimbursement within prevailing healthcare payment systems. Reimbursement and healthcare payment systems in international markets vary significantly by country, and by region in some countries, and include both government-sponsored healthcare and private insurance. We may not obtain international reimbursement approvals in a timely manner, if at all. In addition, even if we do obtain international reimbursement approvals, the level of reimbursement may not be enough to commercially justify expansion of our business into the approving jurisdiction. To the extent we or our customers are unable to obtain reimbursement for products in major international markets in which we seek to market and sell our products, our international revenue growth would be harmed, and our business and results of operations would be adversely affected.
Paragraph 280 · 37% changed Every version of it
Act prohibits both domestic and international bribery across both private and public sectors. We have implemented policies and procedures designed to ensure compliance by us and our directors, officers, employees, representatives, consultants consultants, and agents with the FCPA, OFAC restrictions, the Bribery Act and other export control, anti-corruption, anti-money-laundering and anti-terrorism laws and regulations. We cannot be certain, however, However, given that we sell our policies and procedures are products to government or will be sufficient or that directors, officers, employees, representatives, consultants and agents have not engaged and will not engage in conduct for which government-affiliated entities, we may be held responsible, nor can we provide assurance that our exposed to heightened risk of potential violations of the FCPA, the Bribery Act, or other anti-bribery or anti-corruption laws. In addition, various government agencies may require export licenses, or may seek to impose modifications to business partners have not engaged practices, including cessation of business activities in sanctioned countries or with sanctioned persons or entities, and will not engage in conduct that could materially affect their ability modifications to perform their contractual obligations to us or even result in our being held liable for such conduct. compliance programs, which may increase costs. Violations of the FCPA, OFAC restrictions, the Bribery Act or other export control, anti-corruption, anti-money laundering and anti-terrorism laws or regulations may result in severe criminal or civil sanctions, and we may be subject to other potential liabilities, which could have a material adverse effect on our business, financial condition condition, and results of operations.

MD&A

93 paragraphs · 11 new · 36 reworded · 10 gone · 10-K Feb 24, 2026 against Feb 27, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 36 · 41% changed
Interest expense was $14.4 $13.8 million and $10.8 $14.4 million for the years ending December 31, 2024 2025 and 2023, respectively. The increase was due primarily to 2024, respectively, and consisted of interest expense on the $460.0 million principal amount of the Notes, Notes that carry a 1.5% interest rate and interest expense on the $60.0 million principal amount of the CIBC loan that carries a variable interest rate, which were issued in May 2023. was 5.7% as of December 31, 2025.
Paragraph 31 · 37% changed
Overall gross margin was 60% and 59% and 64% for the years ended December 31, 2024 2025 and 2023, 2024, respectively. The decrease in gross margin from 2023 to 2024 was driven primarily by an increase in service revenue, which has a lower gross margin than product revenue. Gross margin from net product revenue was 79% for each of the years ended December 31, 2025 and 77% 2024. Gross margin from service revenue was 29% and 28% for the years ended December 31, 2024 2025 and 2023, respectively. The increase in product gross margin was primarily as a result of increased sales volume and increased sales of higher margin OCS disposable sets. Gross margin from service revenue was 28% and 29% for the years ended December 31, 2024 and 2023, 2024, respectively, and consisted primarily of organ procurement, OCS perfusion management and transplant logistics services under our NOP. The decrease in service gross margin was primarily due to investments in our NOP network, including aviation-related expenditures, to prepare for future growth. Service revenue gross margin for the year ended December 31, 2023, included the introduction of transportation and logistics services and the integration of Summit.
Paragraph 75 · 30% changed
We intend to may acquire additional fixed-wing aircraft as we scale to enhance our fleet of aircraft. logistics capabilities and support international expansion. During the year ended December 31, 2024, 2025, we acquired eight 3 transplant-related fixed-wing aircraft with an aggregate purchase price of $109.6 million and we plan to acquire additional aircraft in 2025, including two aircraft purchased in January 2025 and February 2025 with an aggregate purchase price of $28.4 $42.9 million.
Paragraph 69 · 24% changed
We believe that our existing cash will enable us to fund our operating expenses, capital expenditure requirements, and debt service payments for at least 12 months following the filing of our annual report on Form 10-K. We may need to raise additional funding, which might not be available on favorable terms or at all. See “Item 1A. Risk Factors—Risks Related to Our Financial Position and Need for Additional Capital” in this Annual Report on Form 10-K.
Paragraph 29 · 22% changed
Revenue from customers in the United States related to OCS transplant was $421.9 $584.7 million in the year ended December 31, 2024 2025 and increased by $200.5 $162.8 million compared to the year ended December 31, 2023, 2024, primarily due to higher sales volumes of our OCS Liver and OCS Heart disposable sets. Revenue for each organ in the table above includes net product revenue from sales of disposable sets as well as service revenue for organ procurement, OCS perfusion management and transplant logistics services under the NOP in the United States. Establishing the NOP, which launched in late 2021, has allowed us to broaden our customer base and increase utilization of the OCS in organ transplantation. Substantially all of our Revenue from customers in outside the United States now participate was $16.7 million and $15.3 million in the NOP. By adding logistics to our NOP offering in late 2023, we have been able to further increase product years ended December 31, 2025 and service revenue. 2024, respectively.
Paragraph 65 · 21% changed
•the costs associated with maintaining maintaining, improving and improving expanding our commercial operations, including the NOP; NOP globally;
Paragraph 6 · 21% changed
Prior to 2024, we had incurred significant annual operating losses since inception and we have only recently achieved profitability. Our ability to generate revenue sufficient to achieve sustained profitability will depend on the continued commercial sales of our products and services. We generated total revenue of $605.5 million and had net income of $190.3 million for the year ended December 31, 2025. We generated total revenue of $441.5 million and had net income of $35.5 million for the year ended December 31, 2024. As of December 31, 2025, we had an accumulated deficit of $278.0 million. We expect our operating and capital expenditures will continue to increase as we focus on growing commercial sales of our products in both the United States and select non-U.S. markets. Because of the numerous risks and uncertainties associated with product development, commercialization and regulations of our industry, we are unable to accurately predict the timing or amount of increased expenses or if we will be able to maintain profitability. Until such time, if ever, as we can generate substantial revenue sufficient to achieve sustained profitability, we may finance our operations through a combination of equity offerings, debt financings and strategic alliances. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms or at all. If we are unable to raise capital or enter into such agreements as, and when, needed, we will have to delay, scale back or discontinue the further development and commercialization efforts of one or more of our products, or may be forced to terminate our operations.
Paragraph 7 · 20% changed
The United Network for Organ Sharing, or UNOS, operated the OPTN under a sole-vendor federal contract from 1986 until 2024. In March 2023, the U.S. Department of Health and Human Services’ Health Resources and Services Administration, or HRSA, announced initiatives designed to improve the OPTN, including its intent to solicit contract proposals to manage the OPTN, which is currently operated by the United Network for Organ Sharing, or UNOS, OPTN under a multi-vendor model following the expiration of the sole-vendor contract that expired in between UNOS and HRSA on March 29, 2024. Additionally, in September 2023, the Securing the U.S. Organ Procurement and Transplantation Network Act was signed into law and law. This legislation expressly authorizes HRSA to award multiple grants, contracts or cooperative agreements to support the operation of the OPTN and OPTN. It also specifies that the awards to operate the OPTN shall be operated through awards that are distinct from awards made to support the organization tasked with supporting the networks’ board of directors. In September 2024, HRSA began awarding contracts aimed at supporting these initiatives. The impact that the HRSA initiatives and the U.S. Organ Procurement and Transplantation Network Act may have on our business, including on our NOP, is uncertain at this time. multi-vendor model.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors314 words changed in this paragraph; it is 34% similar to last year's version.
As we grow our international presence, we are increasingly exposed subject to trade and economic anti-corruption laws, anti-money laundering laws, export control laws, customs laws, sanctions laws and other restrictions laws and regulations imposed by the United States, the European Union and other governments and organizations. organizations in countries where we operate. The U.S. Departments of Justice, Commerce, State and State, and the U.S. Treasury and other federal agencies and authorities have authorities, may seek to impose a broad range of civil and criminal penalties they may seek to impose against corporations and individuals for violations of economic sanctions laws, export control laws, the FCPA FCPA, and other federal statutes and regulations, including those established by the Office of Foreign Assets Control, or OFAC. In addition, the Bribery Act prohibits both domestic and international bribery, as well as bribery across both private and public sectors. The substantive offences of offering or receiving a bribe will be committed by an individual where either the bribery takes place in the U.K, or the person paying or receiving the bribe has a close connection with the UK An organization which is either incorporated in or carries on part of its business in the U.K will be liable under the Bribery Act if a person associated with the organization (being persons performing services for it) pays a bribe anywhere in the world intending to obtain or retain business for the organization. This is a strict liability offense with the only defenses available being that the organization implemented “adequate procedures” to prevent bribery or it was reasonable for it to not have such procedures in place. Under these laws and regulations, as well as other anti-corruption laws, anti-money laundering laws, export control laws, customs laws, sanctions laws and other laws governing our operations, various government agencies may require export licenses, may seek to impose modifications to business practices, including cessation of business activities in sanctioned countries or with sanctioned persons or entities and modifications to compliance programs, which may increase compliance costs, and may subject us to fines, penalties and other sanctions. A violation of these laws or regulations would negatively affect our business, financial condition and results of operations. Due to sales of our products to government or government-affiliated entities, we may be exposed to heightened risk of potential violations of the FCPA, the Bribery Act, or other relevant law.

Source: Item 1A, 10-K 0001193125-26-067032 vs Item 1A, 10-K 0000950170-25-029104

MD&A245 words changed in this paragraph; it is 41% similar to last year's version.
Total selling, general and administrative expenses increased by $49.1 $16.6 million from $119.6 million in the year ended December 31, 2023 to $168.6 million in the year ended December 31, 2024 due primarily to increases $185.2 million in personnel related costs, and facility related and other costs. the year ended December 31, 2025. Personnel related costs increased by $36.8 $5.0 million primarily due to the continued expansion an increase in stock-based compensation expense of our team $3.2 million and increases in contractor and recruiting costs to support the growth of our organization, partially offset by a decrease in our business. Stock-based personnel costs due to less time spent supporting marketing, finance and administrative activities. Personnel related costs included stock-based compensation expense of $30.8 million and $27.6 million for the years ending December 31, 2025 and 2024, respectively. Professional and consultant fees increased by $11.0 million, $7.6 million due primarily to additional grants increased audit and tax-related fees and legal costs related to new patents as well as increased professional and existing employees and the modification legal fees related to an independent review of stock awards pursuant business practices following allegations raised in a short seller report released in January 2025. We also incurred higher consulting services related to the transition agreement with general business initiatives to support our former Chief Financial Officer. growth. Facility related and other costs increased by $11.3 $9.4 million due primarily to increased costs associated with post-approval studies depreciation and amortization and information technology infrastructure costs, and depreciation and amortization expense due to the growth costs as well as increases in our business. Professional and consultant fees increased non-income based state taxes. These increases were partially offset by $0.9 a decrease in NOP support costs of $5.5 million due primarily to increased fees in 2024 related to information technology less activity supporting selling, general and other enterprise solutions costs to support the growth in our business. Professional and consultant fees in the year ended December 31, 2023 included transaction costs of $2.0 million related to our Summit acquisition. administrative functions.

Source: Item 7, 10-K 0001193125-26-067032 vs Item 7, 10-K 0000950170-25-029104

Legal Proceedings200 words changed in this paragraph; it is 48% similar to last year's version.
On February 14, 2025, a class action captioned Merly Jewik v. TransMedics Group, Inc., et al., Case No. 1:25-cv-10385, was filed against the Company and certain of its current and former officers in the United States U.S. District Court for the District of Massachusetts. The complaint purports purported to assert claims against the Company and certain of its current and former officers pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, 1934 (the “Exchange Act”), as amended, and SEC Rule 10b-5 promulgated thereunder, seeking unspecified damages on behalf of a putative class of investors who purchased or otherwise acquired the Company’s shares between February 28, 2023 and January 10, 2025 (the “class period”). Plaintiff seeks to recover damages allegedly caused by “Class Period”). On April 2, 2025, another purported misstatements stockholder filed a putative class action lawsuit against the Company and omissions contained in certain risk disclosures set forth of its current and former officers, also in the Company’s 2022 and 2023 Annual Reports. The complaint alleges the disclosures at issue were false or misleading, because they failed to describe what plaintiff alleges were coercive business and marketing tactics, anticompetitive conduct and fraudulent billing activities on the part of the Company. The complaint claims these alleged statements and omissions operated to artificially inflate the price paid U.S. District Court for the Company's common stock during District of Massachusetts (Collins v. TransMedics Group, Inc., et al., Case No. 1:25-cv-10778). The Collins complaint alleged claims substantially similar to those alleged in the class period. Jewik action and also sought unspecified damages. On May 22, 2025, the court consolidated the Jewik and Collins actions and appointed the Peace Officers’ Annuity and Benefit Fund of Georgia and Oguzhan Altun as lead plaintiffs (the “Lead Plaintiffs”).

Source: Item 3, via Note 12 – Commitments and Contingencies, 10-K 0001193125-26-067032 vs Item 3, via Note 13 – Commitments and Contingencies, 10-K 0000950170-25-029104

Accounting Policies184 words changed in this paragraph; it is 33% similar to last year's version.
In November 2023, September 2025, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): 2025-06, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Targeted Improvements to Reportable Segment Disclosures, the Accounting for Internal-Use Software, which removes all references to software development project stages and requires public entities to disclose information about their reportable segments’ significant expenses start capitalizing software costs when both of the following occur: (i) management has authorized and other segment items on an interim committed to funding the software project and annual basis. Public entities with a single reportable segment are required (ii) it is probable that the project will be completed and the software will be used to apply perform the disclosure requirements function intended. The amendments in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is 2025-06 are effective for fiscal years beginning after December 15, 2023, 2027, and for interim periods within those fiscal years beginning after December 15, 2024, years, with early adoption permitted. permitted as of the beginning of a fiscal year. The amendments can be applied prospectively, retrospectively, or via a modified prospective transition method. The Company adopted is currently assessing the impact of the adoption of this guidance as of January 1, 2024, and the adoption did not have a material impact on its consolidated financial statements.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001193125-26-067032 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0000950170-25-029104

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of TMDX's Risk Factors and MD&A, 10-K Feb 24, 2026 against 10-K Feb 27, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
•the costs associated with maintaining and growing our transplant logistics capabilities, including by means of attracting, training and retaining pilots, and the acquisition, maintenance, or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments;
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
In order to manufacture the OCS in quantities sufficient to meet our anticipated commercial opportunity, we will need to continue to increase our manufacturing capabilities and retain third parties to sterilize our products. We anticipate that our new
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
Inventory levels in excess of customer demand may result in a portion of our inventory becoming obsolete or expiring, as well as inventory write-downs or write-offs. Conversely, if we underestimate customer demand for our products or our own requirements
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
As part of our services offered under our NOP, we have acquired a fleet of fixed-wing aircraft. All of the aircraft we currently operate are standardized variants of a certificated model produced by a single manufacturer. Parts and services from this manufacturer
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
We may experience disruptions as we continue to expand our operations and facilities and execute on our growth strategy. In January 2026, we entered into a lease agreement with the intent to move our headquarters to a larger space in Somerville, Massachusetts. We intend to renovate the facility before moving our operations, including manufacturing, to this facility. The process of moving our business, opening new facilities and bringing operations online at this new site is inherently complex and is not part of our day-to-day operations. The relocation and expansion of our headquarters and the opening of any additional new facilities, including our planned expansion in Italy, may cause significant disruption to our operations, divert management attention and resources and involve significant costs, all of which could have a material adverse effect on our business, financial condition and results of operations. The relocation of our headquarters and any additional facilities that we seek to open may take longer than anticipated or may not proceed as planned, and the expected benefits may be less than anticipated.
Read it in 10-K Feb 24, 2026 at sec.gov
Show the other 56
AddedRisk Factors
We are expanding our operations outside the United States, which increases operational complexity and may require significant management attention and resources. Our international operations involve increased logistics and supply chain complexity, foreign customs and trade requirements, and reliance on third-party service providers, which may result in delays or increased costs. Operating internationally also exposes us to legal and compliance risks, as well as differing healthcare systems and reimbursement frameworks that may limit adoption of our OCS technologies, NOP services or related offerings or reduce expected revenues and margins, If we are unable to effectively manage these risks, our business, financial conditions and results of operations could be materially and adversely affected.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
We currently make limited use of AI technologies in our operations, and we may continue to explore further use cases. The rapid advancement of these technologies presents opportunities for us in research, manufacturing, commercialization, and other business endeavors, but also entails risks, including that AI-generated content, analyses, or recommendations we utilize could be deficient, that our competitors may more quickly or effectively adopt AI capabilities, or that our use of AI or other emerging technologies increases regulatory, privacy, cybersecurity and other significant risks. In addition, any disruption or failure in the AI functionality we incorporate into our business activities, products or services could adversely impact our business or result in delays or errors in our product offerings. The legal and regulatory landscape surrounding AI technologies is rapidly evolving and uncertain, including in the areas of intellectual property, cybersecurity and privacy and data protection. Compliance with new or changing laws, regulations or industry standards relating to AI may impose significant costs on us and limit our ability to effectively develop, deploy or use AI technologies. Furthermore, if we are unable to effectively manage the use of AI technologies by our employees and service providers, our confidential information, intellectual property and reputation could be put at risk. Failure to appropriately respond to this evolving landscape may result in reputational, competitive and business harm as well as litigation and regulatory action and fines, penalties and expenses related thereto.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete. Patent litigation and other proceedings may also absorb significant management time.
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedRisk Factors
•the costs incurred in our efforts to operate and grow our NOP, including the costs and timing of growing our logistics capabilities, inclusive of acquiring and maintaining current and additional aircraft for our aviation transportation services;
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
Furthermore, our ability to utilize our NOLs or credits is conditioned upon our maintaining profitability and generating U.S. federal and state taxable income. As described above, prior to 2024, we incurred significant net losses since inception; and therefore, we do not know whether we will generate the U.S. federal or state taxable income necessary to utilize our NOL or credit carryforwards. Under the Tax Cuts and Jobs Act, or TCJA, NOLs arising in taxable years beginning after December 31, 2017 will not be subject to expiration. In addition, the deduction for NOLs in any taxable year is limited to 80% of annual taxable income in respect of NOLs generated during or after 2018. The TCJA also reduced the corporate income tax rate to 21%, from a prior rate of 35%. This may cause a reduction in the potential economic benefit of our NOLs and other available deferred tax assets.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
We have a limited history of providing aviation transportation services and we continue to depend on certain members of the former management team of Summit for the successful operation and integration into our NOP services offering. Even if we are able to utilize the Bridge to Life Assets and fully realize the benefits of our acquisition of Summit, we may not realize the expected
Read it in 10-K Feb 27, 2025 at sec.gov
RewordedRisk Factors
We expect our operating and capital expenditures will continue to increase for the foreseeable future as we focus on growing commercial sales of our products in both the U.S. and select non-U.S. markets, including growing our NOP; acquiring and maintaining additional aircraft to support aviation transportation; growing expanding our commercial team, which will pursue increasing commercial sales of growing our OCS products; NOP, scaling our manufacturing operations; and sterilization operations, continuing research, development and clinical trial efforts, including expanding our research and development and manufacturing capabilities in Italy, seeking regulatory approval for our the next generation OCS products, including conducting clinical trials for our next generation OCS products; and seeking regulatory clearance for OCS, new products and product enhancements, including new indications, both in both the U.S. United States and in select non-U.S. markets. markets, establishing and relocating to a new long-term global headquarters, and seeking greater control of air and ground transport for our NOP.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
In addition, if these If our single or sole-source suppliers are unable or unwilling to deliver components to us, whether due to a labor shortage, slow down or stoppage, or for any other reason, we would may not be required able to seek alternative suppliers. manufacture or have available one or more products during such period of unavailability and our business could suffer, possibly materially.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
For example, in July 2020, the Court of Justice of the European Union invalidated the U.S.-EU Privacy Shield Framework, which has led There continues to increased be heightened scrutiny of data transfers from the EEA and the UK to the United States generally generally, as well as other jurisdictions, and this may increase our costs of compliance with data privacy legislation.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
For example, in July 2020, the Court of Justice of the European Union invalidated the U.S.-EU Privacy Shield Framework, which has led to increased scrutiny of data transfers from since been replaced by the EEA and the UK to the United States generally and may increase our costs of compliance with data privacy legislation. EU-U.S.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
In addition, a corporation that undergoes an “ownership change,” generally defined in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an “ownership change,” generally defined as a greater than 50% change by value in its equity ownership over a three-year period, is subject to limitations on its ability to utilize its pre-change NOLs, NOLs and its research and development credit carryforwards and its disallowed interest expense carryovers to offset future taxable income.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
If we are unable to obtain patent term extension or restoration or extension, the term of any such extension is less than we request, or the scope of patent protection is less than we would expect it to be during extension period, the period during which we can could enforce our patent rights for the applicable product will may be shortened and our competitors may obtain approval of competing products following our patent expiration. sooner.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
To be placed on the market in Great Britain after this date, medical devices must have undergone a conformity assessment in accordance with UK legislation and have the UKCA mark affixed. affixed (although the UK Government has announced its intent to consult on the indefinite recognition of the CE mark, which may change the time frame for UKCA mark requirements).
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
As we grow our international presence, we are increasingly exposed subject to trade and economic anti-corruption laws, anti-money laundering laws, export control laws, customs laws, sanctions laws and other restrictions laws and regulations imposed by the United States, the European Union and other governments and organizations. organizations in countries where we operate.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
The data we collect from our prior, ongoing and planned clinical studies and patient registry may not be deemed sufficient for this purpose in to support a coverage determination finding by CMS or a Medicare contractor. contractor that use of the OCS is reasonable and necessary such that coverage is warranted.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
For example, we are subject to the requirements of the GDPR, which imposes more stringent administrative requirements for controllers and processors of personal data, including, for example, shortened demanding timelines for notifying personal data breach notifications, breaches, limitations on retention of personal information, increased stringent requirements pertaining to the processing of health data and data, rules regulating pseudonymized (i.e., key-coded) data, additional obligations when we contract with service providers, provider processors, and more robust rights for individuals over with respect to their personal data.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Our products have been and may in the future be subject to product recalls that U.S. federal government shutdowns could harm our reputation and could materially and adversely affect our business, financial condition, operating results, cash flows and prospects.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Proceedings challenging our patents could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
Alternatively, if the Business Litigation Session of the Superior Court of Suffolk County, Massachusetts or a court outside of Massachusetts were to find this exclusive forum provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings described above, we may incur additional costs associated with resolving such matters in other venues or jurisdictions, which could materially and adversely affect our business, financial condition, operating results, cash flows and prospects.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
HRSA has consistently exercised options to extend the contract for UNOS to operate OPTN, albeit in a more limited capacity, since March 2024. Most recently, in December 2025, HRSA and UNOS reached a new agreement that took effect on December 30, 2025. This contract allows HRSA to extend UNOS’ work for up to 12 months, until December 29, 2026, structured as four optional three-month periods. The new agreement reflects a shift of several former UNOS functions, including patient safety, reporting and tracking of donor-derived transmission events, and committee support, to HRSA or other contractors.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
HRSA continues to implement efforts to improve and modernize the OPTN, including enhancements to patient data on organ procurement, expanded transparency through a publicly accessible data dashboard for allocation out of sequence (AOOS) events, expanded outreach and financial support for living organ donors, and a new OPTN fee collection process whereby HRSA directly collects and distributes patient registration fees under authorities originally granted by the 2025 Full-Year Continuing Appropriations and Extensions Act and extended by the 2026 Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act. The impact that HRSA's initiatives and the U.S. Organ Procurement and Transplantation Network Act may have on our business, including on our NOP, is uncertain at this time.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Research, development and clinical trials expenses consist of costs incurred for research activities, product development, hardware and software engineering and clinical trial activities, including salaries and related costs, including stock-based compensation, facilities costs, laboratory supplies, depreciation, testing, regulatory, data management and consulting costs.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Our (provision) benefit for income taxes is based on taxable income (loss), applicable income tax rates, net research and development tax credits, net operating loss carryforwards, changes in valuation allowance estimates and deferred income taxes. During the fourth quarter of 2025, we concluded that it was more likely than not that we will realize substantially all of our net U.S. federal and state deferred tax assets and accordingly, recognized a benefit to income tax expense of $103.3 million related to the release of our valuation allowance. We relied primarily on cumulative income over the preceding twelve quarters, recent operating profits and, to a lesser extent, expected future profits in our assessment to release the valuation allowance. We maintained a valuation allowance of $0.9 million on certain state tax attributes as we considered it more-likely-than-not that these tax attributes would expire before realization.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
As a result of the release of our valuation allowance we expect our income tax rate will increase in the future. To the extent allowed, we intend to use our available net operating loss carryforwards and tax credits to reduce cash tax payment obligations.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Total selling, general and administrative expenses increased by $16.6 million from $168.6 million in the year ended December 31, 2024 to $185.2 million in the year ended December 31, 2025. Personnel related costs increased by $5.0 million primarily due to an increase in stock-based compensation expense of $3.2 million and increases in contractor and recruiting costs to support the growth of our organization, partially offset by a decrease in personnel costs due to less time spent supporting marketing, finance and administrative activities. Personnel related costs included stock-based compensation expense of $30.8 million and $27.6 million for the years ending December 31, 2025 and 2024, respectively. Professional and consultant fees increased by $7.6 million due primarily to increased audit and tax-related fees and legal costs related to patents as well as increased professional and legal fees related to an independent review of business practices following allegations raised in a short seller report released in January 2025. We also incurred higher consulting services related to general business initiatives to support our growth. Facility related and other costs increased by $9.4 million due primarily to increased depreciation and amortization and information technology infrastructure costs as well as increases in non-income based state taxes. These increases were partially offset by a decrease in NOP support costs of $5.5 million due primarily to less activity supporting selling, general and administrative functions.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
We had an income tax benefit of $82.8 million for 2025, as compared to a provision for income tax of $0.3 million in 2024. Our effective tax rate was (77.0%) and 0.9% for 2025 and 2024, respectively. Our effective tax rate for 2025 differs from the U.S. federal statutory income tax rate of 21.0% primarily due to the release of a U.S. valuation allowance. In the fourth quarter of 2025, we concluded that it is more likely than not that substantially all of our U.S. deferred tax assets are realizable, resulting in a valuation allowance release of $103.3 million. Our effective tax rate for 2024 differs from the U.S. federal statutory income tax rate of 21.0% primarily due to excess stock compensation deductions, partially offset by state and federal income taxes for the portion of our taxable income that was not offset by operating loss and tax credit carryforwards, and the impact from the change in valuation allowance.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
On January 8, 2026, we entered into a lease agreement for space in Somerville, Massachusetts to eventually replace our existing headquarters in Andover, Massachusetts. Base rent begins to accrue in the first quarter of 2028 and the initial lease term expires 192 months from the date base rent begins to accrue, unless earlier terminated. The annual base rent under this lease will initially be $23.9 million and will be subject to a 2% annual increase during the first three years of the initial lease term and a 3% annual increase for each year thereafter during the remainder of the initial lease term. On January 8, 2026, we acquired two parcels adjacent to the leased premises in Somerville, Massachusetts for a purchase price of $15.0 million for each property.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
In July 2025, we purchased two parcels of land in Mirandola, Italy. We plan to construct research and development and manufacturing facilities but have not yet entered into constructions contracts.
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedMD&A
Prior to our acquisition in 2023, Summit derived its revenue primarily from charter flight services. To a lesser extent, Summit also derived revenue from providing flight school training, managing aircraft and other related services. As part of the Summit integration, we transitioned Summit's charter flight and aircraft management customers to third parties. We do not anticipate generating revenue from charter flights or aircraft management and related services. We are continuing to offer flight school training services. During the years ended December 31, 2024 and 2023 service revenue of $4.4 million and $4.9 million, respectively, was from Summit's legacy operations, unrelated to the NOP and organ transplant.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
Research, development and clinical trials expenses consist primarily of costs incurred for our research activities, product development, hardware and software engineering, clinical trials to continue to develop clinical evidence of our products’ safety and effectiveness, regulatory expenses, testing, consultant services and other costs associated with our OCS technology platform and OCS products, which include:
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
•employee-related expenses, including salaries, related benefits and stock-based compensation expense for employees engaged in research, hardware and software development, regulatory and clinical trial functions, and recruiting and temporary service fees related to such personnel;
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
•expenses incurred in connection with the clinical trials of our products, including under agreements with third parties, such as consultants, contractors and data management organizations;
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
Total selling, general and administrative expenses increased by $49.1 million from $119.6 million in the year ended December 31, 2023 to $168.6 million in the year ended December 31, 2024 due primarily to increases in personnel related costs, and facility related and other costs. Personnel related costs increased by $36.8 million primarily due to the continued expansion of our team to support the growth in our business. Stock-based compensation expense increased by $11.0 million, due primarily to additional grants to new and existing employees and the modification of stock awards pursuant to the transition agreement with our former Chief Financial Officer. Facility related and other costs increased by $11.3 million due primarily to increased costs associated with post-approval studies and information technology infrastructure costs, and depreciation and amortization expense due to the growth in our business. Professional and consultant fees increased by $0.9 million due primarily to increased fees in 2024 related to information technology and other enterprise solutions costs to support the growth in our business. Professional and consultant fees in the year ended December 31, 2023 included transaction costs of $2.0 million related to our Summit acquisition.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
Income taxes for the years ended December 31, 2024 and 2023 included a tax provision of $0.3 million and less than $0.1 million, respectively, related to state and foreign income taxes. For the year ended December 31, 2023, we also recorded a tax benefit of $1.7 million for the release of a portion of our valuation allowance related to the net deferred tax liabilities recorded in purchase accounting. As part of the allocation of the purchase price of Summit, we recorded deferred tax liabilities for the differences between the fair value recognized in purchase accounting and the tax basis of property, plant and equipment and intangible assets. The net deferred tax liability is a source of income to support the recognition of a portion of our existing deferred tax assets. Therefore, we released the same amount of our valuation allowance. We maintain a valuation allowance on our overall net deferred tax asset as we deem it more likely than not that the net deferred tax asset will not be realized.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
Changes in accounts receivable, inventory, prepaid expenses and other current assets, accounts payable, and accrued expenses and other current liabilities in each reporting period are generally due to growth in our business and timing of invoices and payments.
Read it in 10-K Feb 27, 2025 at sec.gov
RewordedMD&A
Net cash used provided by changes in our operating assets and liabilities for the year ended December 31, 2024 2025 consisted primarily of an increase a decrease in accounts receivable of $34.3 $14.0 million and a net increase in accounts payable and accrued expenses and other current liabilities of $17.7 million, partially offset by an increase in inventory of $8.4 $7.7 million and an increase in prepaid expenses and other current assets of $6.3 million, partially offset by an increase in accounts payable and accrued expenses and other current liabilities of $6.5 $3.8 million.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
A conditional conversion feature of the Notes was triggered on June 30, 2024 and again on September 30, 2024, December 31, 2025, as the last reported sale price of our common stock was greater than or equal to 130% of the conversion price of the Notes for at least 20 trading days during the period of 30 consecutive trading days ending on and including the last trading day of each of the quarters quarter ended June 30, 2024 and September 30, 2024, respectively, December 31, 2025, and the Notes therefore became convertible at the noteholders’ election in the immediately following calendar quarters ended September 30, 2024 and December quarter ending March 31, 2024, respectively. 2026 (and only during this calendar quarter).
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Other Interest income and other income (expense), net also included $1.0 million of realized and unrealized foreign currency transactions gains for the year ended December 31, 2025, and $0.7 million of realized and unrealized foreign currency transactions losses for the year ended December 31, 2024, and $0.3 million of realized and unrealized foreign currency transactions gains during the year ended December 31, 2023. 2024.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
During the year ended December 31, 2024, 2025, we acquired eight 3 transplant-related fixed-wing aircraft with an aggregate purchase price of $109.6 million and we plan to acquire additional aircraft in 2025, including two aircraft purchased in January 2025 and February 2025 with an aggregate purchase price of $28.4 $42.9 million.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Department of Health and Human Services’ Health Resources and Services Administration, or HRSA, announced initiatives designed to improve the OPTN, including its intent to solicit contract proposals to manage the OPTN, which is currently operated by the United Network for Organ Sharing, or UNOS, OPTN under a multi-vendor model following the expiration of the sole-vendor contract that expired in between UNOS and HRSA on March 29, 2024.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2025 2024 2023 Change (in thousands) Personnel related (including stock-based $ 25,720 $ 21,927 $ 15,489 $ 6,438 3,793 compensation expense) Laboratory supplies and research materials 17,550 13,990 7,939 6,051 3,560 Consulting and third-party services 15,492 12,920 5,788 7,132 2,572 Clinical trials costs 1,459 478 1,077 (599) 981 Facility related and other 8,834 6,653 5,762 891 2,181 Total research, development and clinical $ 69,055 $ 55,968 $ 36,055 $ 19,913 13,087 trials expenses
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2025 2024 2023 Change (in thousands) Personnel related (including stock-based $ 114,506 $ 109,475 $ 72,717 $ 36,758 5,031 compensation expense) Professional and consultant fees 25,936 18,313 17,401 912 7,623 NOP support 6,826 12,289 11,985 304 (5,463) Tradeshows and conferences 4,316 4,328 4,575 (247) (12) Facility related and other 33,584 24,212 12,875 11,337 9,372 Total selling, general and administrative $ 185,168 $ 168,617 $ 119,553 $ 49,064 16,551 expenses
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
During the year ended December 31, 2024, 2025, operating activities provided $48.8 $192.8 million of cash, primarily resulting from our net income of $35.5 $190.3 million and net non-cash charges of $58.3 million, partially offset by net cash used provided by changes in our operating assets and liabilities of $45.0 $18.4 million, partially offset by net non-cash income of $15.8 million.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2025 2024 2023 2022 (in thousands) Net cash provided by (used in) operating activities $ 192,840 $ 48,803 $ (13,028) $ (45,817) Net cash provided by (used in) used in investing activities (59,251) (129,303) (193,953) 54,513 Net cash provided by financing activities 16,857 22,874 400,418 167,927 Effect of exchange rate changes on cash, cash equivalents and 1,270 (536) 193 (1,021) restricted cash Net increase (decrease) in cash, cash equivalents and restricted cash $ 151,716 $ (58,162) $ 193,630 $ 175,602
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Total research, development and clinical trials expenses increased by $19.9 $13.1 million from $36.1 million in the year ended December 31, 2023 to $56.0 million in the year ended December 31, 2024. 2024 to $69.1 million in the year ended December 31, 2025.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
As we continue to pursue and increase commercial sales of our OCS products, we expect our costs and expenses to increase in the future, particularly as we expand our commercial team, grow our NOP, scale our manufacturing and sterilization operations, continue research, development and clinical trial efforts, including expanding our research and development and manufacturing capabilities in Italy, seek regulatory approval for the next generation OCS, new products and product enhancements, including new indications, both in the United States and in select non-U.S. markets, establish and relocate to a new long-term global headquarters, and seek greater control of air and ground transport for our NOP.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
United States Lung total revenue $ 13,443 $ 15,755 $ 10,548 $ 5,207 Heart total revenue 111,839 96,663 59,080 37,583 Liver total revenue 459,415 309,462 151,719 157,743 Total United States OCS transplant revenue 584,697 421,880 221,347 200,533 All other countries Lung total revenue 1,418 1,926 1,272 654 Heart total revenue 14,169 13,198 14,012 (814) Liver total revenue 1,113 158 104 54 Total all other countries OCS transplant 16,700 15,282 15,388 (106) revenue Total OCS transplant revenue $ 601,397 $ 437,162 $ 236,735 $ 200,427
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesMD&A
With the acquisition of Summit in August 2023, the purchase of fixed-wing transplant aircraft and the addition of a logistics team, we anticipate have increased service revenue from our transplant logistics services.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesMD&A
For example, if If the demand for our products exceeds our existing manufacturing and sterilization capacity, our ability to fulfill orders would be limited until we have sufficiently expanded such operations.
Read it in 10-K Feb 24, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TMDX/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.